{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361981469799877376.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.jpba.2004.10.022"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0731708504005448?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0731708504005448?httpAccept=text/plain"}}],"dc:title":[{"@value":"Protonation equilibrium and lipophilicity of moxifloxacin"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381981469799877377","@type":"Researcher","foaf:name":[{"@value":"Marie-Hélène Langlois"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469799877504","@type":"Researcher","foaf:name":[{"@value":"Martine Montagut"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469799877379","@type":"Researcher","foaf:name":[{"@value":"Jean-Pierre Dubost"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469799877378","@type":"Researcher","foaf:name":[{"@value":"Jean Grellet"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469799877376","@type":"Researcher","foaf:name":[{"@value":"Marie-Claude Saux"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"07317085"},{"@type":"PISSN","@value":"https://id.crossref.org/issn/07317085"}],"prism:publicationName":[{"@value":"Journal of Pharmaceutical and Biomedical Analysis"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2005-02","prism:volume":"37","prism:number":"2","prism:startingPage":"389","prism:endingPage":"393"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0731708504005448?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0731708504005448?httpAccept=text/plain"}],"createdAt":"2004-12-09","modifiedAt":"2020-04-04","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1390001204272431232","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pharmacodynamic profile and clinical efficacy of moxifloxacin ophthalmic solution (VegamoxTM 0.5% ophthalmic solution)"},{"@language":"ja","@value":"モキシフロキサシン点眼液（ベガモックス点眼液０．５％）の薬理学的特性および臨床効果"},{"@value":"新薬紹介総説 モキシフロキサシン点眼液(ベガモックス点眼液0.5%)の薬理学的特性および臨床効果"},{"@language":"ja-Kana","@value":"シンヤク ショウカイ ソウセツ モキシフロキサシン テンガンエキ ベガモックス テンガンエキ 0 5% ノ ヤクリガクテキ トクセイ オヨビ リンショウ コウカ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679604733056","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Permeability of Pig Urinary Bladder Wall: Time and Concentration Dependent Effect of Chitosan"}]},{"@id":"https://cir.nii.ac.jp/crid/1390846609810761344","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A Validated Spectrofluorimetric Method for the Determination of Moxifloxacin in Its Pure Form, Pharmaceutical Preparations, and Biological Samples"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.jpba.2004.10.022"},{"@type":"CROSSREF","@value":"10.1248/bpb.29.1685_references_DOI_ZBoyowoErtR5b3tulIHXs0yNJFq"},{"@type":"CROSSREF","@value":"10.1254/fpj.129.375_references_DOI_ZBoyowoErtR5b3tulIHXs0yNJFq"},{"@type":"CROSSREF","@value":"10.2116/analsci.19p370_references_DOI_ZBoyowoErtR5b3tulIHXs0yNJFq"}]}